


UNDERSTANDING REGARDING
ARTICLE 2 ANNEX 26-A ON TRANSPARENCY AND PROCEDURAL FAIRNESS
FOR PHARMACEUTICAL PRODUCTS AND MEDICAL DEVICES

4 February, 2016


The Governments of Brunei Darussalam and the Republic of Peru have reached the following understanding concerning the Annex 26-A (Transparency and Procedural Fairness for Pharmaceutical Products and Medical Devices) contained in Chapter 26 (Transparency and Anti-Corruption) of the Trans-Pacific Partnership Agreement signed this day:

The Parties recognise that with regard to Article 2 (Principles), it is understood that “high-quality health care” does not refer to specific final outcomes in a Party’s healthcare system, including the selection of specific pharmaceutical products.

This understanding is set out in the English and Spanish languages. In the event of any divergence between the texts, the English language version shall prevail.



FOR THE GOVERNMENT OF
BRUNEI DARUSSALAM



FOR THE GOVERNMENT OF
THE REPUBLIC OF PERU